NanoPharmaceuticals

NanoPharmaceuticals is a clinical-stage pharmaceutical company developing molecularly targeted drugs that bind thyrointegrin alpha-v beta-3 receptors over-expressed in cancers. Researchers have defined the previously unrecognized anticancer attributes of tetraiodothyroacetic acid, a naturally occurring derivative of L-thyroxine.

Its molecularly targeted macromolecules bind thyrointegrin alpha-v beta-3 receptors over-expressed in cancers and their associated microenvironment. BG-P-TAT is a dual-targeting agent for thyrointegrin alpha-v beta-3 receptors and the norepinephrine transporter, both differentially expressed in neuroendocrine cancers. An advanced preclinical candidate is aimed at the treatment of neuroblastoma and other neuroendocrine cancers.